STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth  in vivo

Torstein Lindstad; Su Qu; Jørgen Sikkeland; Yang Jin; Alexandr Kristian; Gunhild M. Mælandsmo; Philippe Collas; Fahri Saatcioglu

doi:10.18632/oncotarget.11131

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo

Torstein Lindstad, Su Qu, Jørgen Sikkeland, Yang Jin, Alexandr Kristian, Gunhild M. Mælandsmo, Philippe Collas and Fahri Saatcioglu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:91817-91827. https://doi.org/10.18632/oncotarget.11131

Metrics: PDF 1603 views | HTML 3831 views | ?

Abstract

Torstein Lindstad1, Su Qu1, Jørgen Sikkeland1,2, Yang Jin1,2, Alexandr Kristian3, Gunhild M. Mælandsmo3, Philippe Collas4 and Fahri Saatcioglu1,2

1Department of Biosciences, University of Oslo, Oslo, Norway

2Department of Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway

3Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

4Institute of Basic Medical Sciences, Norwegian Center for Stem Cell Research, University of Oslo, Oslo, Norway

Correspondence to:

Fahri Saatcioglu, email: [email protected]

Keywords: STAMP2, ASC, lipogenesis, adipogenesis, prostate cancer

Received: May 24, 2016 Accepted: July 01, 2016 Published: August 09, 2016

ABSTRACT

Six Transmembrane Protein of Prostate 2 (STAMP2) has been implicated in both prostate cancer (PCa) and metabolic disease. STAMP2 has unique anti-inflammatory and pro-metabolic properties in mouse adipose tissue, but there is limited information on its role in human metabolic tissues. Using human adipose-derived stem cells (ASCs), we report that STAMP2 expression is dramatically upregulated during adipogenesis. shRNA-mediated STAMP2 knockdown in ASCs significantly suppresses adipogenesis and interferes with optimal expression of adipogenic genes and adipocyte metabolic function. Furthermore, ASC-derived adipocyte-mediated stimulation of prostate tumor growth in nude mice is significantly reduced upon STAMP2 knockdown in ASC adipocytes. These results suggest that STAMP2 is crucial for normal ASC conversion into adipocytes and their metabolic function, as well as their ability to facilitate PCa growth in vivo.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11131

Publication Alerts

Research Papers:

STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo

Abstract